Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with TQB2450 for advanced gynecologic malignancies
ChiCTR2000037106Phase 2Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and benmelstobart in gynecological cancer, sponsored by Shanghai Tenth People's Hospital. Primary endpoints: objective response rate and adverse events. Started Oct 2020; status: recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
gynecological cancer
Beyond the preview
Go deeper on ChiCTR2000037106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037106.